Sudeep Pharma Ltd Q1 FY27 Earnings Analysis

- Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28. - Specialty Ingredients segment forecasted to continue similar growth as in the past 2-3 years, maintaining strong momentum. - Bisglycinate product category projected to become a sizable revenue contributor starting FY28. - With the greenfield facility operational, pharma food nutrition volumes have grown over 20%, expecting further growth with capacity expansion. - Battery materials volume is expected to scale up, with a fair assumption of selling around 2,500 metric tons in FY27. - Overall, the company confident about sustaining momentum in FY27 with focus on higher-value products and deeper global customer engagement. - Excluding battery materials, business can scale up to approximately INR 1000-1200 crores revenue without additional capex.

- FY27 is expected to mark an important inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals. - Pharma food nutrition segment is expected to grow faster than the 10% growth seen in FY26. - Specialty ingredients vertical to maintain similar growth rates seen in the last 2-3 years. - Margins to recover to historical levels around 37-38% EBITDA by FY27 after current upfront investments. - Excluding battery materials, business can scale to INR 1000-1200 crores revenue without incremental capex. - Battery materials segment (at full 100,000 tons capacity) could generate INR 1600-1800 crores revenue. - Overall margins expected to return to historical averages (24-25% PAT margin) once investments and new teams start contributing positively. - Focus remains on margin expansion through higher-value product mix and efficient operations over time.

- **Battery Materials Project at Dahej**: Phase 1 capacity of 25,000 metric tons yearly, commissioning by April 2027. Total target capacity up to 100,000 metric tons with approx. INR 600 crores capex planned. - **Greenfield Manufacturing Project**: Focused on pharma, food, and nutrition verticals, enhancing capabilities for high-value mineral molecules like glycinate and gluconate. Internal production validation completed; customer qualification ongoing. - **Capex in FY26**: INR 127 crores (including INR 34 crores for SAM land, INR 80 crores Greenfield project, INR 13 crores maintenance). - **Capex in FY27**: Expected around INR 10 crores to complete Greenfield project, plus maintenance capex of INR 15 crores in core business; additional capex for battery materials projects continues. - **Strategic investments**: Expansion of commercial presence, technical teams, inventory, and warehousing in North America and Europe for Specialty Ingredients and Pharma Food Nutrition verticals.

- In the FY26 earnings call, there was no explicit mention of any new fundraising plans through debt or equity. - The company reported a comfortable leverage position with net debt at INR33.6 crores and a net debt-to-equity ratio of 0.04x as of March 31, 2026. - Capex for FY27 is expected to be moderate, with major greenfield expansions largely completed and maintenance capex around INR15 crores. - The battery materials project’s upcoming expansion (up to 100,000 metric tons capacity) involves a total capex estimate of around INR600 crores, but no specific fundraising plans were disclosed. - Overall, the management focused on operational growth and margin improvement without indicating immediate plans for raising funds through debt or equity.

- Sudeep Pharma has a strong order book with ongoing commercial purchase orders, including approximately 700 metric tons for battery materials received recently. - The company is engaged with 42 global customers across the cathode, cell, EV, and ESS ecosystem; 22 at lab validation, 14 at pilot scale, and 6 at commercial validation. - For battery materials, customer engagement and qualification progress are encouraging, with active off-take discussions. - Specialty ingredients segment has good visibility with approvals from large global customers in encapsulation technology and infant nutrition premix categories. - The company expects the specialty ingredients segment to maintain its growth momentum in FY27. - For FY27, a commercial sale of around 2,500 metric tons of battery-grade iron phosphate is a fair volume assumption. - Overall, momentum across both verticals (pharma food nutrition and specialty ingredients) is expected to continue growing in FY27 and FY28.